CD133-Positive Cells from Non-Small Cell Lung Cancer Show Distinct Sensitivity to Cisplatin and Afatinib

Archivum Immunologiae et Therapiae Experimentalis

Volumn 63, Issue 3, 2015, Pages 207-214

  Alama, Angela ^a   Gangemi, Rosaria ^a   Ferrini, Silvano ^a   Barisione, Gaia ^a   Orengo, Anna Maria ^a   Truini, Mauro ^a   Bello, Maria Giovanna Dal ^a   Grossi, Francesco ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

Afatinib; CD133; Cisplatin; Drug resistance; EpCAM; NSCLC

Indexed keywords

AFATINIB; CD133 ANTIGEN; CELL ADHESION MOLECULE; CISPLATIN; EGFR PROTEIN, HUMAN; EPCAM PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; GLYCOPROTEIN; LEUKOCYTE ANTIGEN; PEPTIDE; QUINAZOLINE DERIVATIVE; TUMOR ANTIGEN;

CANCER STEM CELL; CARCINOMA, NON-SMALL-CELL LUNG; COMBINATION DRUG THERAPY; DRUG EFFECTS; DRUG RESISTANCE; GENETICS; HUMAN; LUNG NEOPLASMS; METABOLISM; PHYSIOLOGY; TUMOR CELL LINE;

ANTIGENS, CD; ANTIGENS, NEOPLASM; CARCINOMA, NON-SMALL-CELL LUNG; CELL ADHESION MOLECULES; CELL LINE, TUMOR; CISPLATIN; DRUG RESISTANCE, NEOPLASM; DRUG THERAPY, COMBINATION; GLYCOPROTEINS; HUMANS; LUNG NEOPLASMS; NEOPLASTIC STEM CELLS; PEPTIDES; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84939986143     PISSN: 0004069X     EISSN: 16614917     Source Type: Journal    
DOI: 10.1007/s00005-015-0330-5     Document Type: Article

References (26)

1. Abhold EL, Kiang A, Rahimy E et al (2012) EGFR kinase promotes acquisition of stem cell-like properties: a potential therapeutic target in head and neck squamous cell carcinoma stem cells. PLoS One 2:e32459
2. Alama A, Orengo AM, Ferrini S et al (2012) Targeting cancer-initiating cell drug-resistance: a roadmap to a new-generation of cancer therapies? Drug Discov Today 17:435–442
3. Bertolini G, Roz L, Perego P et al (2009) Highly tumorigenic lung cancer CD133 cells display stem-like features and are spared by cisplatin treatment. Proc Natl Acad Sci USA 106:16281–16286
4. Chang A (2011) Chemotherapy, chemoresistance and the changing treatment landscape for NSCLC. Lung Cancer 71:3–10
5. Chen S, Huo X, Lin Y et al (2010) Association of MDR1 and ERCC1 polymorphisms with response and toxicity to cisplatin-based chemotherapy in non-small-cell lung cancer patients. Int J Hyg Environ Health 213:140–145
6. Chen Y, Yu D, Zhang H et al (2012) CD133(+)EpCAM(+) phenotype possesses more characteristics of tumor initiating cells in hepatocellular carcinoma Huh7 cells. Int J Biol Sci 8:992–1004
7. Cufer T, Ovcaricek T, O’Brien ME (2013) Systemic therapy of advanced non-small cell lung cancer: major-developments of the last 5-years. Eur J Cancer 49:1216–1225
8. Favoni RE, Alama A (2013) Preclinical strategies targeted at non-small-cell lung cancer signalling pathways with striking translational fallout. Drug Discov Today 18:11–24
9. Ferlay J, Shin HR, Bray F et al (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127:2893–2917
10. Galvani E, Giovannetti E, Saccani F et al (2013) Molecular mechanisms underlying the antitumor activity of 3-aminopropanamide irreversible inhibitors of the epidermal growth factor receptor in non–small cell lung cancer. Neoplasia 15:61–72
11. Gottschling S, Herpel E, Eberhardt WE et al (2012) The gefitinib long-term responder (LTR)—a cancer stem-like cell story? Insights from molecular analyses of German long-term responders treated in the IRESSA expanded access program (EAP). Lung Cancer 77:183–191
12. Levina V, Marrangoni AM, DeMarco R et al (2008) Drug-selected human lung cancer stem cells: cytokine net-work, tumorigenic and metastatic properties. PLoS One 3:e3077
13. Li D, Ambrogio L, Shimamura T et al (2008) BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene 27:4702–4711
14. Maugeri-Saccà M, Vigneri P, De Maria R (2011) Cancer stem cells and chemosensitivity. Clin Cancer Res 17:4942–4947
15. Mazzoleni S, Politi LS, Pala M et al (2010) Epidermal growth factor receptor expression identifies functionally and molecularly distinct tumor-initiating cells in human glioblastoma multiforme and is required for gliomagenesis. Cancer Res 70:7500–7513
16. Munz M, Baeuerle PA, Gires O (2009) The emerging role of EpCAM in cancer and stem cell signaling. Cancer Res 69:5627–5629
17. Neuzil J, Stantic M, Zobalova R et al (2007) Tumor-initiating cells vs. cancer ‘stem’ cells and CD133: what’s in the name? Biochem Biophys Res Commun 355:855–859
18. Nguyen KS, Kobayashi S, Costa DB (2009) Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway. Clin Lung Cancer 10:281–289
19. Nguyen LV, Vanner R, Dirks P et al (2012) Cancer stem cells: an evolving concept. Nat Rev Cancer 12:133–143
20. Ono M, Kuwano M (2006) Molecular mechanisms of epidermal growth factor receptor (EGFR) activation and response to gefitinib and other EGFR-targeting drugs. Clin Cancer Res 12:7242–7251
21. Pao W, Miller V, Zakowski M et al (2004) EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 101:13306–13311
22. Peacock CD, Watkins N (2008) Cancer stem cells and the ontogeny of lung cancer. J Clin Oncol 26:2883–2889
23. Singh S, Trevino J, Bora-Singhal N et al (2012) EGFR/Src/Akt signaling modulates Sox2 expression and self-renewal of stem-like side-population cells in non-small cell lung cancer. Mol Cancer 11:73
24. Skirecki T, Hoser G, Kawiak J et al (2014) Flow cytometric analysis of CD133- and EpCAM-positive cells in the peripheral blood of patients with lung cancer. Arch Immunol Ther Exp 62:67–75
25. Tan DS, Gerlinger M, Teh BT et al (2010) Anti-cancer drug resistance: understanding the mechanisms through the use of integrative genomics and functional RNA interference. Eur J Cancer 46:2166–2177
26. Zandi R, Larsen AB, Andersen P et al (2007) Mechanisms for oncogenic activation of the epidermal growth factor receptor. Cell Signal 19:2013–2023